Neumora Therapeutics, Inc. (NMRA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.74

From 52W high−79.67%

Volume3.88M

Market cap$137.16M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$0.74

From 52W high

−79.67%

Volume

3.88M

Market cap

$137.16M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

17.4

MomentumView details →

1D Return

−2.67%

YTD Return

−59.80%

SummaryUpdated Jun 1, 2026

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Watertown, Massachusetts. The company went public in September 2023 and focuses on developing novel therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Originally incorporated as RBNC Therapeutics, Inc., the company changed its name to Neumora Therapeutics in October 2021. Neumora is currently advancing multiple clinical-stage programs targeting conditions that affect approximately 1.5 billion people worldwide, with its lead program being navacaprant for major depressive disorder.

Ask drillr about Neumora Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−477.87%

ROA (TTM)

−169.86%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+21.66%

FCF YoY

+7.74%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+5.23%

EBITDA YoY

+20.23%

MomentumView details →

1D Return

−2.67%

YTD Return

−59.80%

1Y Return

−59.12%

RSI (14)

17.4

vs 50D SMA

−50.77%

vs 200D SMA

−64.04%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

4.50x

Quick Ratio

4.50x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.23

EPS Surprise

4.20%

Beats (12Q)

4/12

Next Q EPS Est

−$0.20

Avg Surprise (4Q)

5.17%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−212.75M

Op. CF (TTM)

−180.52M

Next earningsNov 5, 2026 →

Latest newsMore news →

Paul L. Berns stepped down as Executive Chairperson of the Board of Directors of Neumora Therapeutics, Inc., effective August 14, 2026.38d ago

Doron Sagman, M.D., FRCPC was appointed Chief Medical Officer of Neumora Therapeutics, Inc., effective August 14, 2026.38d ago

Similar companies

Caribou Biosciences, Inc.CRBU Conexeu Sciences Inc.CNXU ADC Therapeutics S.A.ADCT TuHURA Biosciences, Inc.HURA Unicycive Therapeutics, Inc.UNCY Biomea Fusion, Inc.BMEA Find similar companies →

Latest newsMore news →

Paul L. Berns stepped down as Executive Chairperson of the Board of Directors of Neumora Therapeutics, Inc., effective August 14, 2026.38d ago Doron Sagman, M.D., FRCPC was appointed Chief Medical Officer of Neumora Therapeutics, Inc., effective August 14, 2026.38d ago Joshua Pinto, Ph.D. was promoted to Chief Executive Officer and President, and Class III director of the Board of Directors of Neumora Therapeutics, Inc., effective August 14, 2026.38d ago